Moderna, Inc. (NASDAQ:MRNA) Shares Acquired by 180 Wealth Advisors LLC

180 Wealth Advisors LLC lifted its holdings in Moderna, Inc. (NASDAQ:MRNA) by 3.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 18,557 shares of the company’s stock after buying an additional 578 shares during the quarter. 180 Wealth Advisors LLC’s holdings in Moderna were worth $772,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. State Street Corp lifted its position in shares of Moderna by 12.1% during the 3rd quarter. State Street Corp now owns 16,847,212 shares of the company’s stock valued at $1,125,899,000 after acquiring an additional 1,823,276 shares during the period. Geode Capital Management LLC grew its holdings in shares of Moderna by 2.6% in the 3rd quarter. Geode Capital Management LLC now owns 7,069,580 shares of the company’s stock worth $470,670,000 after acquiring an additional 178,115 shares during the period. Wellington Management Group LLP increased its stake in Moderna by 21.0% in the 3rd quarter. Wellington Management Group LLP now owns 5,224,685 shares of the company’s stock valued at $349,166,000 after purchasing an additional 906,114 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Moderna by 0.5% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,890,812 shares of the company’s stock worth $260,023,000 after purchasing an additional 19,819 shares during the last quarter. Finally, The Manufacturers Life Insurance Company boosted its position in Moderna by 6.2% during the third quarter. The Manufacturers Life Insurance Company now owns 3,073,934 shares of the company’s stock worth $205,431,000 after purchasing an additional 178,939 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company’s stock.

Analysts Set New Price Targets

MRNA has been the subject of several research reports. Wolfe Research began coverage on Moderna in a research note on Friday, November 15th. They set an “underperform” rating and a $40.00 price target for the company. Leerink Partners dropped their target price on shares of Moderna from $60.00 to $48.00 and set an “underperform” rating for the company in a report on Tuesday, September 17th. Barclays reduced their price target on shares of Moderna from $125.00 to $111.00 and set an “overweight” rating on the stock in a report on Friday, November 8th. Needham & Company LLC reissued a “hold” rating on shares of Moderna in a research note on Friday, November 8th. Finally, Berenberg Bank began coverage on Moderna in a research note on Tuesday, November 19th. They issued a “hold” rating and a $42.00 target price on the stock. Four equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $78.83.

Moderna Stock Down 2.0 %

MRNA opened at $34.46 on Wednesday. Moderna, Inc. has a 12 month low of $31.94 and a 12 month high of $170.47. The business has a 50-day moving average of $41.78 and a two-hundred day moving average of $67.79. The company has a debt-to-equity ratio of 0.05, a current ratio of 4.39 and a quick ratio of 4.20. The stock has a market capitalization of $13.26 billion, a price-to-earnings ratio of -5.92 and a beta of 1.60.

Moderna (NASDAQ:MRNA) last released its earnings results on Thursday, November 7th. The company reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.89) by $1.92. The firm had revenue of $1.90 billion during the quarter, compared to the consensus estimate of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. Moderna’s revenue was up 3.8% compared to the same quarter last year. During the same period in the previous year, the firm earned ($1.39) earnings per share. On average, research analysts expect that Moderna, Inc. will post -9.3 earnings per share for the current year.

Insider Activity

In other news, insider Shannon Thyme Klinger sold 1,418 shares of the business’s stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $42.79, for a total transaction of $60,676.22. Following the completion of the sale, the insider now owns 19,717 shares in the company, valued at approximately $843,690.43. The trade was a 6.71 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold 2,664 shares of company stock valued at $115,210 in the last ninety days. Company insiders own 15.70% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.